LHEI
SKYE icon

Leo H. Evart Inc’s Skye Bioscience SKYE Stock Holding History

Leo H. Evart Inc’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 294

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Leo H. Evart Inc's SKYE Position: Q1 2026 in Review

Leo H. Evart Inc opened a new position in Skye Bioscience (SKYE) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #294 among its holdings.

39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Leo H. Evart Inc held 1 share of Skye Bioscience worth $1 as of Q1 2026.
  • Skye Bioscience was a new Leo H. Evart Inc position in Q1 2026.
  • Skye Bioscience made up ﹤0.01% of Leo H. Evart Inc's portfolio in Q1 2026, its #294 holding.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Leo H. Evart Inc's 13F filing for Q1 2026, filed 13 May 2026.